Astrazeneca Plc Loss Submission Form

See If You Qualify For Monetary Reward

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

Submit Transaction Detail Now (Optional)

- OR -

    An attorney-client relationship is not created with the submission of this form, nor an obligation on the part of Levi & Korsinsky or you to file a lead plaintiff motion in this matter . The information you submit is held as confidential. If, in its sole discretion, Levi & Korsinsky believes that you might be an appropriate lead plaintiff candidate, Levi & Korsinsky will contact you to discuss the matter and whether to establish an attorney client relationship. By submitting this form, you are authorizing us to contact you regarding this case and/or future cases. Additionally, by submitting this form, you agree to receive an email providing you with login details for CORE (Compensation Recovery Monitoring System) to help you monitor and track your securities. This is a complimentary service. Thank you for submitting your details to Levi & Korsinsky.

    FAX: 212-363-7171

    Levi & Korsinsky, LLP announces that a AZN class action lawsuit has been filed on behalf of investors who purchased Astrazeneca Plc (AZN) securities between May 21, 2020 and November 20, 2020. For more on the AZN Lawsuit please contact us today.

    According to the Astrazeneca Plc lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:

    (a) initial clinical trials for the Company’s COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca’s clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.

    If you suffered a loss in Astrazeneca Plc you have until March 29, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.